Development of Orphan Drugs in Japan: Characteristics of Orphan Drugs Developed in Japan-Reference-Cited by-同舟云学术

Development of Orphan Drugs in Japan: Characteristics of Orphan Drugs Developed in Japan

Published:2000-07 Issue:3 Volume:34 Page:839-846
ISSN:0092-8615
Container-title:Drug Information Journal
language:en
Short-container-title:Drug Information J

Author:

Shiragami Makoto,Nakai Kiyohito

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug guides,Pharmacology (nursing)

Link

http://link.springer.com/content/pdf/10.1177/009286150003400320.pdf

Reference5 articles.

1. Hirai T, Urayama T. Intractable diseases and orphan drugs. Farumashia. 1995;31(7):770–778.

2. Shulman SR, Mancocchia M. The US Orphan Drug Programme. Pharmacoeconomics. 1997:12:312–326.

3. Organization for Pharmaceutical Safety and Research ed. Orphan Drug Development Promotion System. Tokyo, Japan: Organization for Pharmaceutical Safety and Research; 1999.

4. Morning Paper of Nihon Keizai Shimbun. February 16, 1999.

5. Ohtaki Y, et al. Venture business and university. EAJ Information. 1999;81:1–25.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan;F1000Research;2023-11-13

2. Pharmaceutical policy and innovation for rare diseases: A narrative review;F1000Research;2023-11-13

3. Pharmaceutical policy and innovation for rare diseases: A narrative review;F1000Research;2023-02-24

4. Rare diseases and orphan drugs in Japan: developing multiple strategies of regulation and research;Expert Opinion on Orphan Drugs;2013-08-26

5. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives;Intractable & Rare Diseases Research;2012